Revere Pharmaceuticals

About:

Revere Pharmaceuticals develops a drug discovery and development platform targeting Rac1 and its genomic variants.

Website: https://reverepharma.com/

Description:

Revere Pharmaceuticals specializes in precision medicine to address unmet needs in cancer and other diseases by targeting Rac1 GTPase proteins that were once considered undruggable. It has developed an innovative drug discovery and development platform that drives its small molecule pipeline targeting Rac1 and its genomic variants. The platform combines in silico modeling and proprietary assays with high-throughput screening capabilities to discover novel Rac1 and Cdc42 inhibitors. These enable the delivery of novel targeted therapeutics.

Total Funding Amount:

$4.51M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Arlington, Massachusetts, United States

Founded Date:

2016-01-01

Contact Email:

info(AT)reverepharma.com

Founders:

Robert Silverman

Number of Employees:

1-10

Last Funding Date:

2021-09-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai